JUNSHI BIO (HKG: 01877) shares opened sharply higher, gaining more than 11%. At the time of writing, the stock is up 11.11% to HK$18.5, with a turnover of HK$1.6724 million.

The significant move follows the company's announcement of a licensing agreement. On June 30, 2026, the company entered into an Authorization License Agreement with its counterparty.

Details of the Strategic Deal

Under the terms of the agreement, JUNSHI BIO has granted exclusive rights for the development, registration, production, and commercialization of the collaboration product, known as nuokaoqi bai dan kang (JS005, an anti-IL-17A monoclonal antibody), within the Greater China region. This region encompasses mainland China, Hong Kong, Macau, and Taiwan.

Financial Terms and Milestones

As part of the deal, JUNSHI BIO will receive an upfront payment of RMB 215 million, which is non-deductible and non-refundable. Furthermore, the company is eligible to receive development and sales milestone payments that could total up to RMB 1.125 billion. Additionally, JUNSHI BIO will earn tiered royalties based on a double-digit percentage of the net sales generated in the Greater China region.